BMJ Best Practice

参考文献

关键文献

Pappas G, Papadimitriou P, Akritidis N, et al. The new global map of human brucellosis. Lancet Infect Dis. 2006;6:91-99.

Dean AS, Crump L, Greter H, et al. Global burden of human brucellosis: a systematic review of disease frequency. PLoS Negl Trop Dis. 2012;6:e1865.

Dean AS, Crump L, Greter H, et al. Clinical manifestations of human brucellosis: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2012;6:e1929.

Franco MP, Mulder M, Gilman RH, et al. Human brucellosis. Lancet Infect Dis. 2007;7:775-786.

Al Dahouk S, Sprague LD, Neubauer H. New developments in the diagnostic procedures for zoonotic brucellosis in humans. Rev Sci Tech. 2013;32:177-188.

Skalsky K, Yahav D, Bishara J, et al. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ. 2008;336:701-704.

Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, et al. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev. 2012;(10):CD007179.

参考文章

1.  Madkour MM. Madkour's brucellosis. 2nd ed. New York, NY: Springer-Verlag; 2001.

2.  Pappas G, Akritidis N, Bosilkovski M, et al. Brucellosis. N Engl J Med. 2005;352:2325-2336.

3.  Hasanjani Roushan MR, Moherez M, Smailnejad Gangi SM, et al. Epidemiological features and clinical manifestations in 469 adult patients with brucellosis in Babol, Northern Iran. Epidemiol Infect. 2004;132:1109-1114.

4.  Andriopoulos P, Tsironi M, Deftereos S, et al. Acute brucellosis: presentation, diagnosis, and treatment of 144 cases. Int J Infect Dis. 2007;11:52-57.

5.  Pappas G, Papadimitriou P, Akritidis N, et al. The new global map of human brucellosis. Lancet Infect Dis. 2006;6:91-99.

6.  Young EJ. An overview of human brucellosis. Clin Infect Dis. 1995;21:283-289.

7.  Pappas G. The changing Brucella ecology: novel reservoirs, new threats. Int J Antimicrob Agents. 2010;36(suppl 1):S8-S11.

8.  Mantur BG, Amarnath SK, Shinde RS. Review of clinical and laboratory features of human brucellosis. Indian J Med Microbiol. 2007;25:188-202.

9.  Gwida M, Al Dahouk S, Melzer F, et al. Brucellosis - regionally emerging zoonotic disease? Croat Med J. 2010;51:289-295.

10.  Guerrier G, Daronat JM, Morisse L, et al. Epidemiological and clinical aspects of human Brucella suis infection in Polynesia. Epidemiol Infect. 2011;139:1621-1625.

11.  Ekpanyaskul C, Santiwattanakul S, Tantisiriwat W, et al. Factors associated with seropositive antibodies to Brucella melitensis in the Nakhon Nayok, Thailand. J Med Assoc Thai. 2012;95(suppl 12):S40-S46.

12.  Lewis J, Taegtmeyer M, Murray S, et al. Brucellosis, human, melitensis – UK ex Thailand (Nakom Pathom). ProMED-mail. May 2015. http://promedmail.org/ (last accessed 26 August 2016).

13.  Godfroid J, Cloeckaert A, Liautard JP, et al. From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis. Vet Res. 2005;36:313-326.

14.  Zinsstag J, Schelling S, Wyss K, et al. Potential of cooperation between human and animal health to strengthen health systems. Lancet. 2005;366:2142-2145.

15.  Kunda J, Fitzpatrick J, Kazwala R, et al. Health-seeking behaviour of human brucellosis cases in rural Tanzania. BMC Public Health. 2007;7:315.

16.  Dean AS, Crump L, Greter H, et al. Global burden of human brucellosis: a systematic review of disease frequency. PLoS Negl Trop Dis. 2012;6:e1865.

17.  Almuneef MA, Memish ZA, Balkhy HH, et al. Importance of screening household members of acute brucellosis cases in endemic areas. Epidemiol Infect. 2004;132:533-540.

18.  Mendoza-Núñez M, Mulder M, Franco MP, et al. Brucellosis in household members of Brucella patients residing in a large urban setting in Peru. Am J Trop Med Hyg. 2008;78:595-598.

19.  Memish ZA, Balkhy HH. Brucellosis and international travel. J Travel Med. 2004;11:49-55.

20.  Dahouk SA, Neubauer H, Hensel A, et al. Changing epidemiology of human brucellosis, Germany, 1962-2005. Emerg Infect Dis. 2007;13:1895-1900.

21.  Pike RM. Laboratory-associated infections: summary and analysis of 3921 cases. Health Lab Sci. 1976;13:105-114.

22.  Harding AL, Byers KB. Epidemiology of laboratory-associated infections. In: Fleming DO, Hunt DL, eds. Biological safety: principles and practices. 3rd ed. Washington, DC: ASM Press; 2000:35-36.

23.  Ergonul O, Celikbas A, Tezeren D, et al. Analysis of risk factors for laboratory-acquired Brucella infections. J Hosp Infect. 2004;56:223-227.

24.  Yagupsky P, Baron EJ. Laboratory exposures to brucellae and implications for bioterrorism. Emerg Infect Dis. 2005;11:1180-1185.

25.  Bouza E, Sanchez-Carrillo C, Hernangomez S, et al. Laboratory-acquired brucellosis: a Spanish national survey. J Hosp Infect. 2005;61:80-83.

26.  Centers for Disease Control and Prevention (CDC). Laboratory-acquired brucellosis - Indiana and Minnesota, 2006. MMWR Morb Mortal Wkly Rep. 2008;57:39-42.

27.  Reddy S, Manuel R, Sheridan E, et al. Brucellosis in the United Kingdom - a risk to laboratory workers? Recommendations for prevention and management of laboratory exposure. J Clin Pathol. 2010;63:90-92.

28.  Knudsen A, Kronborg G, Dahl Knudsen J, et al. Laboratory exposure to Brucella melitensis in Denmark: a prospective study. J Hosp Infect. 2013;85:237-239.

29.  Traxler RM, Lehman MW, Bosserman EA, et al. A literature review of laboratory-acquired brucellosis. J Clin Microbiol. 2013;51:3055-3062.

30.  Beeching NJ, Whatmore AM, Corbel MJ. Brucellosis. In: Fauci AS, Braunwald E, Kasper DL,et al, eds. Harrison’s principles of internal medicine. 19th ed. New York, NY: McGraw-Hill; 2014: chap 192.

31.  Beeching NJ, Madkour MM. Brucellosis. In: Farrar J, Hotez P, Junghanss T, et al, eds. Manson’s tropical diseases. 23rd ed. London: Elsevier; 2013:371-378, 378.e1.

32.  De BK, Stauffer L, Koylass MS, et al. Novel Brucella strain (BO1) associated with a prosthetic breast implant infection. J Clin Microbiol. 2008;46:43-49.

33.  Scholz HC, Nöckler K, Göllner C, et al. Brucella inopinata sp. nov., isolated from a breast implant infection. Int J Syst Evol Microbiol. 2010;60:801-808.

34.  Jiménez de Bagüés MP, Iturralde M, Arias MA, et al. The new strains Brucella inopinata BO1 and Brucella species 83-210 behave biologically like classic infectious Brucella species and cause death in murine models of infection. J Infect Dis. 2014;210:467-472.

35.  Sabbaghian H. Fresh white cheese as a cause of Brucella infection. Public Health. 1975;89:165-169.

36.  Entessar F, Ardalan A. Brucella. Geneva: World Health Organization; 1964.

37.  Beeching NJ, Erdem H. Brucellosis. In: Cohen J, Powderly WG, Opal SM, eds. Infectious diseases. 4th ed. London: Elsevier Science; 2016:1098-1101.

38.  Langer AJ, Ayers T, Grass J, et al. Nonpasteurized dairy products, disease outbreaks, and state laws - United States, 1993-2006. Emerg Infect Dis. 2012;18:385-391.

39.  Claeys WL, Cardoen S, Daube G, et al. Raw or heated cow milk consumption: review of risks and benefits. Food Control. 2013;31:251-262.

40.  Guihot A, Bossi P, Bricaire F. Bioterrorism with brucellosis [in French]. Presse Med. 2004;33:119-122.

41.  Flynn MP. Human clinical bovine-type brucellosis not derived from milk. Public Health. 1983;97:149-157.

42.  Kaufmann AF, Fox MD, Boyce JM, et al. Airborne spread of brucellosis. Ann N Y Acad Sci. 1980;353:105-114.

43.  Mantur BG, Mangalgi SS, Mulimani M. Brucella melitensis - a sexually transmissible agent? Lancet. 1996;347:1763.

44.  Gross A, Terraza A, Ouahrani-Bettache S, et al. In vitro Brucella suis infection prevents the programmed cell death of human monocytic cells. Infect immun. 2000;68:342-351.

45.  de Figueiredo P, Ficht TA, Rice-Ficht A, et al. Pathogenesis and immunobiology of brucellosis: review of Brucella-host interactions. Am J Pathol. 2015;185:1505-1517.

46.  Khan MY, Mah WM, Memish ZA. Brucellosis in pregnant women. Clin Infect Dis. 2001;32:1172-1177.

47.  Kurdoglu M, Adali E, Kurdoglu Z, et al. Brucellosis in pregnancy: a 6-year clinical analysis. Arch Gynecol Obstet. 2010;281:201-206.

48.  Paul J, Gilks C, Batchelor B, et al. Serologic responses to brucellosis in HIV-seropositive patients. Trans R Soc Trop Med Hyg. 1995;89:228-230.

49.  Moreno S, Ariza J, Espinosa FJ, et al. Brucellosis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis. 1998;17:319-326.

50.  Syrjamaki C, Migliazzo A, Yarbrough JW, et al. Brucella abortus endocarditis following ingestion of cow's blood. Nebr Med J. 1984;69:141-142.

51.  Greenfield RA, Drevets DA, Machado LJ, et al. Bacterial pathogens as biological weapons and agents of bioterrorism. Am J Med Sci. 2002;323:299-315.

52.  Pappas G, Panagopoulou P, Christou L, et al. Brucella as a biological weapon. Cell Mol Life Sci. 2006;63:2229-2236.

53.  Williams B. Brucellosis. Practitioner. 1982;226:1507-1517.

54.  Gerada A, Beeching NJ. Brucellosis and travel. Travel Med Infect Dis. 2016;14:180-181.

55.  Norman FF, Monge-Maillo B, Chamorro-Tojeiro S, et al. Imported brucellosis: a case series and literature review. Travel Med Infect Dis. 2016;14:182-199.

56.  Bosilkovski M, Rodriguez-Morales AJ. Brucellosis and its particularities in children travelers. Recent Pat Antiinfect Drug Discov. 2014;9:164-172.

57.  Wyatt HV. Brucella melitensis can be transmitted sexually. Lancet. 1996;348:615. [Erratum in: Lancet 1996;348:970.]

58.  Economidou J, Kalafatas P, Vatopolou D, et al. Brucellosis in two thalassaemic patients infected by blood transfusions from the same donor. Acta Haematol. 1976;55:244-249.

59.  Martinez-Canseco J, Hernandez-Ramos I, Macias-Hernandez AE, et al. Unjustified disposal of transfusion blood because of antibodies against Brucella [in Spanish]. Rev Invest Clin. 1996;48:297-300.

60.  World Health Organization. Brucellosis in humans and animals. 2006. http://www.who.int/ (last accessed 26 August 2016).

61.  Luzzi GA, Brindle R, Sockett PN, et al. Brucellosis: imported and laboratory-acquired cases, and an overview of treatment trials. Trans R Soc Trop Med Hyg. 1993;87:138-141.

62.  Government of Alberta Health and Wellness. Brucellosis: public health notifiable disease management guidelines. July 2012. http://www.health.alberta.ca/ (last accessed 26 August 2016).

63.  Robichaud S, Libman M, Behr M, et al. Prevention of laboratory-acquired brucellosis. Clin Infect Dis. 2004;38:e119-e122.

64.  Centers for Disease Control and Prevention. Brucellosis: hunters risks. January 2016. https://www.cdc.gov/ (last accessed 31 August 2016).

65.  Georghiou PR, Young EJ. Prolonged incubation in brucellosis. Lancet. 1991;337:1543.

66.  Mantur BG, Akki AS, Mangalgi SS, et al. Childhood brucellosis - a microbiological, epidemiological and clinical study. J Trop Pediatr. 2004;50:153-157.

67.  Barroso García P, Rodriguez-Contreras Pelayo R, Gil Extremera B, et al. Study of 1,595 brucellosis cases in the Almeria province (1972-1998) based on epidemiological data from disease reporting [in Spanish]. Rev Clin Esp. 2002;202:577-582.

68.  Dean AS, Crump L, Greter H, et al. Clinical manifestations of human brucellosis: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2012;6:e1929.

69.  Franco MP, Mulder M, Gilman RH, et al. Human brucellosis. Lancet Infect Dis. 2007;7:775-786.

70.  Colomenero JD, Reguera JM, Martos F, et al. Complications associated with Brucella melitensis infection: a study of 530 cases. Medicine (Baltimore). 1996;75:195-211. [Erratum in: Medicine (Baltimore) 1997;76:139.]

71.  Uddin MJ, Sanyal SC, Mustafa AS, et al. The role of aggressive medical therapy along with early surgical intervention in the cure of Brucella endocarditis. Ann Thorac Cardiovasc Surg. 1998;4:209-213.

72.  Pappas G, Bosilkovski M, Akritidis N, et al. Brucellosis and the respiratory system. Clin Infect Dis. 2003;37:e95-e99.

73.  Erdem H, Inan A, Elaldi N, et al. Respiratory system involvement in brucellosis: the results of the Kardelen study. Chest. 2014;145:87-94.

74.  Milionis H, Christou L, Elisaf M. Cutaneous manifestations in brucellosis: case report and review of the literature. Infection. 2000;28:124-126.

75.  Al Dahouk S, Sprague LD, Neubauer H. New developments in the diagnostic procedures for zoonotic brucellosis in humans. Rev Sci Tech. 2013;32:177-188.

76.  Gotuzzo E, Carrilo C, Guerra J, et al. An evaluation of diagnostic methods for brucellosis - the value of bone marrow culture. J Infect Dis. 1986;153:122-125.

77.  Doganay M, Aygen B. Human brucellosis: an overview. Int J Infect Dis. 2003;7:173-182.

78.  Yagupsky P. Detection of brucellae in blood cultures. J Clin Microbiol. 1999;37:3437-3442.

79.  Gómez MC, Nieto JA, Rosa C, et al. Evaluation of seven tests for diagnosis of human brucellosis in an area where the disease is endemic. Clin Vaccine Immunol. 2008;15:1031-1033.

80.  Ruiz-Mesa JD, Sanchez-Gonzalez J, Reguera JM, et al. Rose Bengal test: diagnostic yield and use for the rapid diagnosis of human brucellosis in emergency departments in endemic areas. Clin Microbiol Infect. 2005;11:221-225.

81.  Araj GF, Lulu AR, Mustafa MY, et al. Evaluation of ELISA in the diagnosis of acute and chronic brucellosis in human beings. J Hyg (Lond). 1986;97:457-469.

82.  Abdoel TH, Smits HL. Rapid latex agglutination test for the serodiagnosis of human brucellosis. Diagn Microbiol Infect Dis. 2007;57:123-128.

83.  Nielson K, Smith P, Widdison J, et al. Serological relationship between cattle exposed to Brucella abortus, Yersinia enterocolitica O:9 and Escherichia coli O157:H7. Vet Microbiol. 2004;100:25-30.

84.  Ariza J, Pellicer T, Pallares R, et al. Specific antibody profile in human brucellosis. Clin Infect Dis. 1992;14:131-140.

85.  Ashford DA, di Pietra J, Lingappa J, et al. Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51. Vaccine. 2004;22:3435-3439.

86.  Queipo-Ortuño MI, Morata P, Ocón P, et al. Rapid diagnosis of human brucellosis by peripheral-blood PCR assay. J Clin Microbiol. 1997;35:2927-2930.

87.  Mitka S, Anetakis C, Souliou E, et al. Evaluation of different PCR assays for early detection of acute and relapsing brucellosis in humans in comparison with conventional methods. J Clin Microbiol. 2007;45:1211-1218.

88.  Vrioni G, Pappas G, Priavali E, et al. An eternal microbe: Brucella DNA load persists for years after clinical cure. Clin Infect Dis. 2008;46:e131-e136.

89.  Lista F, Reubsaet FA, De Santis R, et al. Reliable identification at the species level of Brucella isolates with MALDI-TOF-MS. BMC Microbiol. 2011;11:267.

90.  Ferreira L, Vega Castaño S, Sánchez-Juanes F, et al. Identification of Brucella by MALDI-TOF mass spectrometry: fast and reliable identification from agar plates and blood cultures. PLoS One. 2010;5:e14235.

91.  Karger A, Melzer F, Timke M, et al. Interlaboratory comparison of intact-cell matrix-assisted laser desorption ionization-time of flight mass spectrometry results for identification and differentiation of Brucella spp. J Clin Microbiol. 2013;51:3123-3126.

92.  Araj GF, Lulu AR, Khateeb MI, et al. ELISA versus routine tests in the diagnosis of patients with systemic and neurobrucellosis. APMIS. 1988;96:171-176.

93.  Erdem H, Kilic S, Sener B, et al. Diagnosis of chronic brucellar meningitis and meningoencephalitis: the results of the Istanbul-2 study. Clin Microbiol Infect. 2013;19:E80-E86.

94.  Yagupsky P, Peled N. Use of the Isolator 1.5 microbial tube for detection of Brucella melitensis in synovial fluid. J Clin Microbiol. 2002;40:3878.

95.  Kokoglu OF, Hosoglu S, Geyik MF, et al. Clinical and laboratory features of brucellosis in two university hospitals in Southeast Turkey. Trop Doct. 2006;36:49-51.

96.  Troy SB, Rickman LS, Davis CE. Brucellosis in San Diego: epidemiology and species-related differences in acute clinical presentations. Medicine (Baltimore). 2005;84:174-187.

97.  Al-Shahed MS, Sharif HS, Haddad MC, et al. Imaging features of musculoskeletal brucellosis. Radiographics. 1994;14:333-348.

98.  Pourbagher A, Pourbagher MA, Savas L, et al. Epidemiologic, clinical, and imaging findings in brucellosis patients with osteoarticular involvement. AJR Am J Roentgenol. 2006;187:873-880.

99.  Erdem H, Elaldi N, Ak O, et al. Genitourinary brucellosis: results of a multicentric study. Clin Microbiol Infect. 2014;20:O847-O853.

100.  Health Protection Agency. Brucellosis: guidelines for action in the event of a deliberate release. September 2009. http://www.hpa.org.uk/ (last accessed 26 August 2016).

101.  Rusnak JM, Kortepeter MG, Aldis J, et al. Experience in the medical management of potential laboratory exposures to agents of bioterrorism on the basis of risk assessment at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). J Occup Environ Med. 2004;46:801-811.

102.  Corbel MJ. Brucellosis: an overview. Emerg Infect Dis. 1997;3:213-221.

103.  Ariza J, Bosilkovski M, Cascio A, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med. 2007;4:e317.

104.  Skalsky K, Yahav D, Bishara J, et al. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ. 2008;336:701-704.

105.  Solís García del Pozo J, Solera J. Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis. PLoS One. 2012;7:e32090.

106.  Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, et al. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev. 2012;(10):CD007179.

107.  Hashemi SH, Gachkar L, Keramat F, et al. Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial. Int J Infect Dis. 2012;16:e247-e251.

108.  Pappas G, Christou L, Akritidis N, et al. Quinolones for brucellosis: treating old diseases with new drugs. Clin Microbiol Infect. 2006;12:823-825.

109.  Bosilkovski M, Kirova V, Grozdanovski K, et al. Doxycycline-rifampin versus doxycycline-rifampin-gentamicin in treatment of human brucellosis. Trop Doct. 2012;42:13-17.

110.  Vrioni G, Bourdakis A, Pappas G, et al. Administration of a triple versus a standard double antimicrobial regimen for human brucellosis more efficiently eliminates bacterial DNA load. Antimicrob Agents Chemother. 2014;58:7541-7544.

111.  Lubani MM, Dudin KI, Sharda DC, et al. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr Infect Dis J. 1989;8:75-78.

112.  Roushan MR, Mohraz M, Janmohammadi N, et al. Efficacy of cotrimoxazole and rifampin for 6 or 8 weeks of therapy in childhood brucellosis. Pediatr Infect Dis J. 2006;25:544-545.

113.  Keshtkar-Jahromi M, Razavi SM, Gholamin S, et al. Medical versus medical and surgical treatment for brucella endocarditis. Ann Thorac Surg. 2012;94:2141-2146.

114.  Pappas G, Akritidis N, Christou L. Treatment of neurobrucellosis: what is known and what remains to be answered. Expert Rev Anti Infect Ther. 2007;5:983-990.

115.  Erdem H, Ulu-Kilic A, Kilic S, et al. Efficacy and tolerability of antibiotic combinations in neurobrucellosis: results of the Istanbul study. Antimicrob Agents Chemother. 2012;56:1523-1528.

116.  Ulu-Kilic A, Karakas A, Erdem H, et al. Update on treatment options for spinal brucellosis. Clin Microbiol Infect. 2014;20:O75-O82.

117.  Centers for Disease Control and Prevention (CDC). Suspected brucellosis case prompts investigation of possible bioterrorism-related activity - New Hampshire and Massachusetts, 1999. MMWR Morb Mortal Weekly Rep. 2000;49:509-512.

118.  Brown CE, Beeching NJ, Cooke RP. Laboratory acquired brucellosis - a review of published reports 1950-2007. Posters, 18th ECCMID, abstract P1852. Clin Microbiol Infect. 2008;14(suppl 7):S542.

使用此内容应接受我们的免责声明